Pregnancy outcomes in PCOS patients undergoing IVF with long GnRH agonist protocol versus flexible GnRH antagonist

IVF is a good option for Polycystic ovary syndrome patients who not respond to ovulation induction treatment. This study was performed with aim to compare pregnancy outcomes in PCOS patients undergoing IVF with long GnRH agonist versus flexible GnRH antagonist regimens. This randomized clinical trial study was performed on 96 infertile PCOS women candidates for IVF who referred to Milad Infertility Center in 2014. The patients were divided into 2 groups: long GnRH agonist and GnRH antagonist. Oral contraceptive pills were prescribed as pretreatment and recombinant FSH was given for ovarian induction. Data were analyzed by SPSS software (version 20) and Chi-square, Exact Fisher, and Mann-Whitney tests. P<0.05 was considered statistically significant. Two groups of GnRH agonist and GnRH antagonist were not significantly different in terms of pregnancy outcomes like chemical pregnancy (p=0.544), clinical pregnancy (p=0.6), abortion (p=1), and multiple pregnancy (p=0.688). The prevalence of Ovarian hyperstimulation syndrome was less in antagonist group versus agonist group that had statistically significant difference (p=0.0001). Dose of gonadotropins (p=0.344) and the number of days of gonadotropins consumption (p=0.236) were not significantly different between two groups. GnRH antagonist can be used in PCOS patient's candidates for IVF. The use of GnRH antagonist is not different in pregnancy outcome compared to GnRH agonist and only decreases the complications of infertility treatment.